Market research
OC5.F Cochlear Limited
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 5B
- P/E ratio
- 60.38
- Analyst target
- Not available
- Dividend yield
- 4.1%
- Beta
- 0.27
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- AU000000COH5
- Market cap
- 5B
- P/E ratio
- 60.38
- Analyst target
- Not available
- Dividend yield
- 4.1%
- Beta
- 0.27
About
About Cochlear Limited
Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers cochlear implant systems; replacement sound processors, accessories, and other services; bone conduction systems and replacement sound processors; and recipient support tools. The company also provides Cochlear connected care solutions, such as Cochlear Nucleus SmartNav System; Cochlear Custom Sound Pro Fitting Software; Cochlear Remote Assist; Cochlear Remote Check; and Cochlear Link. It offers its products and services under the Cochlear, Nucleus, Nexa, Osia, and Cochlear Baha brands. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OC5.F discussion.
5 years, 5 months ago
Cochlear Limited is currently in a long term uptrend where the price is trading 15.2% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.1.
Finally, its free cash flow fell by 46.1% to $34M since the same quarter in the previous year.
Based on the above factors, Cochlear Limited gets an overall score of 2/5.